Mocht u kanker-actueel de moeite waard vinden en ons willen ondersteunen om kanker-actueel online te houden dan kunt u ons machtigen voor een periodieke donatie via donaties: https://kanker-actueel.nl/NL/donaties.html of doneer al of niet anoniem op - rekeningnummer NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Amersfoort. Onze IBANcode is NL79 RABO 0372 9311 38   
 Elk bedrag is welkom. En we zijn een ANBI instelling dus uw donatie of gift is in principe aftrekbaar voor de belasting.

En als donateur kunt u ook korting krijgen bij verschillende bedrijven: 

https://kanker-actueel.nl/NL/voordelen-van-ops-lidmaatschap-op-een-rijtje-gezet-inclusief-hoe-het-kookboek-en-de-recepten-op-basis-van-uitgangspunten-van-houtsmullerdieet-te-downloaden-enof-in-te-zien.html

3 februari 2017: Bron: ASCO en Journal of Clinical Oncology

Op 1 februari 2017 is online een overzichtsrapport verschenen: Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology die de belangrijkste studies bespreekt die afgelopen jaar werden gepubliceerd. En voor het tweede jaar op rij wordt immuuntherapie genoemd als de belangrijkste ontwikkeling.

Vooral de anti-PD medicijn studies (checkpoint remmers) geven steeds goede hoopvolle resultaten bij nagenoeg alle vormen van kanker:

Checkpoint remmers beeld

Fig 2. Immune checkpoint inhibitors: releasing the brakes on the immune system. MHC, major histocompatibility complex; PD-1, programmed death 1; PD-L1, programmed death ligand-1; TCR, T-cell receptor.

Maar ook gerichte medicijnen op bepaalde DNA mutaties en receptorenexpressie spelen grote rol in de nieuwste behandelingen van kanker. Ook preventie en screeening via ook o.a. bloedmonsters krijgen veel aandacht in dit rapport:

A range of other important advances and trends are featured in Clinical Cancer Advances:

  • Precision medicine: Last year brought approvals of new treatments targeting molecules important in the growth of certain types of kidney, lung, breast, and blood cancer.
  • Liquid biopsies: The first test for circulating plasma tumor DNA was approved by the FDA in 2016 for certain patients with lung cancer. This new technology allows physicians to assess key cancer-driving tumor mutations through a simple blood draw, as opposed to invasive tissue biopsies, which in turn facilitates selection of optimal treatment and monitoring changes in the status of the tumor over time.
  • New tools help bridge gaps between patients and physicians: The report highlights a Web-based tool for self-monitoring symptoms that immediately alerts the cancer care team when patients report that a symptom is worsening. In addition, education and patient navigation programs demonstrate ways to increase treatment adherence.

“To conquer cancer, we must conduct research across the cancer care continuum, from screening to new treatments and strategies that help ease treatment side effects,” said Harold J. Burstein, MD, PhD, FASCO, Co-Executive Editor of Clinical Cancer Advances.

Het studierapport isd zo uitgebreid, maar ook veel van wat er in besprken wordt is ook wel op kanker-actueel te vinden dat ik maar niet verder vertaal.

Het studierapport: Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology is op verschillende manieren te bekijken. Op de website van de Journal of Clinical Oncology is het volledige rapport gratis in te zien.

Via ASCO is het rapport als flipbook in te bladeren.

Tot slot als u het studierapport wilt hebben in een PDF document kunt u ons een mailtje sturen: redactie@kanker-actueel.nl  en sturen we het u digitaal toe.

Hier de inleiding tot het rapport met daaronder de referentielijst behorend bij dit studierapport:

A growing number of patients with cancer are benefiting from research advances in immunotherapy, leading ASCO to name immunotherapy as the Society's Advance of the Year for a second year in a row. Clinical Cancer Advances 2017 highlights the expanding role of immunotherapy. Evolving research findings are providing new insights on how to get optimal results from these relatively new treatments.

Source: DOI: 10.1200/JCO.2016.71.5292 Journal of Clinical Oncology - published online before print February 1, 2017

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Harold J. Burstein*, Lada Krilov, Jeanny B. Aragon-Ching†, Nancy N. Baxter†, E. Gabriela Chiorean†, Warren Allen Chow†, John Frederick De Groot†, Steven Michael Devine†, Steven G. DuBois†, Wafik S. El-Deiry†, Andrew S. Epstein†, John Heymach†, Joshua Adam Jones†, Deborah K. Mayer†, Rebecca A. Miksad†, Nathan A. Pennell†, Michael S. Sabel†, Richard L. Schilsky‡, Lynn Mara Schuchter†, Nadine Tung†, Karen Marie Winkfield†, Lori J. Wirth†, and Don S. Dizon*Harold J. Burstein and Steven G. DuBois, Dana-Farber Cancer Institute; Rebecca A. Miksad and Nadine Tung, Beth Israel Deaconess Medical Center; Lori J. Wirth and Don S. Dizon, Massachusetts General Hospital, Boston, MA; Lada Krilov and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria; Jeanny B. Aragon-Ching, Inova Schar Cancer Institute, Fairfax, VA; E. Gabriela Chiorean, University of Washington, Seattle, WA; Warren Allen Chow, City of Hope, Duarte, CA; John Frederick De Groot and John Heymach, University of Texas MD Anderson Cancer Center, Houston, TX; Steven Michael Devine, Ohio State University, Columbus; Nathan A. Pennell, Cleveland Clinic, Cleveland, OH; Wafik S. El-Deiry, Fox Chase Cancer Center; Joshua Adam Jones, University of Pennsylvania Health Systems; Lynn Mara Schuchter, University of Pennsylvania, Philadelphia, PA; Andrew S. Epstein, Memorial Sloan Kettering Cancer Center, New York, NY; Deborah K. Mayer, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill; Karen Marie Winkfield, Wake Forest Baptist Medical Center, Winston-Salem, NC; Michael S. Sabel, University of Michigan, Ann Arbor, MI; and Nancy N. Baxter, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada.

Abstract
A MESSAGE FROM ASCO’S PRESIDENT

I am pleased to present Clinical Cancer Advances 2017, which highlights the most promising advances in patient-oriented cancer research over the past year. The report gives us an opportunity to reflect on what an exciting time it is for cancer research and how swiftly our understanding of cancer has improved.

One year ago, the White House announced the national Cancer Moonshot program to accelerate progress against cancer. This shared vision of progress has reinvigorated the research community, identified new areas of scientific collaboration, and raised our ambitions regarding what may be possible beyond the progress we have already made.

When I entered the field 35 years ago, I could not have imagined where we would be today. We can now detect cancer earlier, target treatments more effectively, and manage adverse effects more effectively to enable patients to live better, more fulfilling lives. Today, two of three people with cancer live at least 5 years after diagnosis, up from roughly one of two in the 1970s.

This progress has resulted from decades of incremental advances that have collectively expanded our understanding of the molecular underpinnings of cancer. There is no better current example of this than ASCO’s 2017 Advance of the Year: Immunotherapy 2.0.

Over the last year, there has been a wave of new successes with immunotherapy. Research has proven this approach can be effective against a wide range of hard-to-treat advanced cancers previously considered intractable. Researchers are now working to identify biologic markers that can help increase the effectiveness of treatment and determine who is most likely to benefit from immunotherapy. This knowledge will enable oncologists to make evidence-based decisions so as many patients as possible might benefit from this new type of treatment.

Each successive advance builds on the previous hard work of generations of basic, translational, and clinical cancer researchers. Importantly, the advances described in this report would not have been possible without the individuals who volunteered to participate in clinical trials as part of their treatment.

To turn the promising vision of a cancer moonshot into meaningful advances, we need sustained, robust federal funding for continued research and innovation. Approximately 30% of the research highlighted in this report was funded, at least in part, through federal dollars appropriated to the National Institutes of Health or the National Cancer Institute. Without this federal investment—unique internationally in scale, duration, and impact for decades—I fear we may lose the forward momentum needed to further the progress we see highlighted in this report.

Federal lawmakers can further fuel progress by advancing initiatives that facilitate the use of big data to achieve the common good of high-quality care for all patients. Such programs, like ASCO’s CancerLinQ, will rapidly increase the pace of progress and dramatically expand the reach of treatment advances to the millions of patients who are living with cancer today or who will do so in the future. This investment will yield medical, scientific, economic, and societal benefits for years to come.

Much work still lies ahead. Many questions remain about how cancer develops and spreads and how best to treat it. As you read through Clinical Cancer Advances 2017, I hope you are as inspired as I am by the gains the clinical cancer research community has made over the past year and by the promise of a new era of advances just over the horizon.

Daniel F Hayes, MD, FASCO, FACP

ASCO President, 2016 to 2017

REFERENCES
1. National Cancer Institute: SEER stat fact sheets: Melanoma of the skin. https://seer.cancer.gov/statfacts/html/melan.html
2. Ribas A, Hamid O, Daud A, et al: Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600-1609, 2016 CrossRef, Medline
3. Topalian SL, Sznol M, McDermott DF, et al: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-1030, 2014
4. Schadendorf D, Hodi FS, Robert C, et al: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889-1894, 2015 Link
5. Postow M, Chesney J, Pavlick A, et al: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL). Presented at the 107th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, April 16-20, 2016 (abstr CT002)
6. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al: Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med [epub ahead of print on October 7, 2016]
7. WHO International Agency for Research on Cancer: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx
8. Herbst RS, Baas P, Kim DW, et al: Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 387:1540-1550, 2016 CrossRef, Medline
9. Reck M, Rodríguez-Abreu D, Robinson AG, et al: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med [epub ahead of print on October 8, 2016]
10. Socinski M, Creelan B, Hom L, et al: CheckMate 026: A phase 3 trial of nivolumab vs investigator’s choice of platinum-based doublet chemotherapy as first-line therapy for stage IV/reccurrent programmed death ligand 1-positive NSCLC. Presented at the 2016 European Society for Medical Oncology, Copenhagen, Denmark, October 7-11, 2016 (abstr LBA7-PR)
11. US Food and Drug Administration: Atezolizumab (TECENTRIQ). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm
12. US Food and Drug Administration: Pembrolizumab (KEYTRUDA) checkpoint inhibitor. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526430.htm
13. National Cancer Institute: SEER stat fact sheets: Bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html
14. American Cancer Society: Bladder cancer. http://www.cancer.org/cancer/bladdercancer/
15. US Food and Drug Administration: FDA approves new, targeted treatment for bladder cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm501762.htm
16. Rosenberg JE, Hoffman-Censits J, Powles T, et al: Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387:1909-1920, 2016 CrossRef, Medline
17. Business Wire: Merck’s KEYNOTE-045 studying KEYTRUDA® (pembrolizumab) in advanced bladder cancer (urothelial cancer) meets primary endpoint and stops early. http://www.businesswire.com/news/home/20161021005182/en/Merck%E2%80%99s-KEYNOTE-045-Studying-KEYTRUDA%C2%AE-pembrolizumab-Advanced-Bladder
18. Balar A, Bellmunt J, O’Donnell PH, et al: Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Presented at the 2016 European Society for Medical Oncology, Copenhagen, Denmark, October 7-11, 2016 (abstr LBA32-PR)
19. Ferlay J, Soerjomataram I, Dikshit R, et al: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015 CrossRef, Medline
20. National Cancer Institute: SEER stat fact sheets: Oral cavity and pharynx cancer. https://seer.cancer.gov/statfacts/html/oralcav.html
21. Ferris RL, Blumenschein G Jr, Fayette J, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med [epub ahead of print on October 8, 2016]
22. US Food and Drug Administration: Nivolumab for SCCHN. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm528920.htm
23. National Cancer Institute: SEER stat fact sheets: Ovarian cancer. https://seer.cancer.gov/statfacts/html/ovary.html
24. Hamanishi J, Mandai M, Ikeda T, et al: Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 33:4015-4022, 2015 Link
25. National Cancer Institute: SEER stat fact sheets: Hodgkin lymphoma. https://seer.cancer.gov/statfacts/html/hodg.html
26. US Food and Drug Administration: Nivolumab (Opdivo) for Hodgkin lymphoma. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm501412.htm
27. Roemer MG, Advani RH, Ligon AH, et al: PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol 34:2690-2697, 2016 Link
28. Younes A, Santoro A, Shipp M, et al: Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17:1283-1294, 2016 CrossRef, Medline
29. Armand P, Shipp MA, Ribrag V, et al: Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34:3733-3739, 2016
30. Zaretsky JM, Garcia-Diaz A, Shin DS, et al: Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819-829, 2016 CrossRef, Medline
31. Roberts SA, Gordenin DA: Hypermutation in human cancer genomes: Footprints and mechanisms. Nat Rev Cancer 14:786-800, 2014 CrossRef, Medline
32. Le DT, Uram JN, Wang H, et al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509-2520, 2015 CrossRef, Medline
33. Bouffet E, Larouche V, Campbell BB, et al: Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206-2211, 2016 Link
34. Nghiem PT, Bhatia S, Lipson EJ, et al: PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374:2542-2552, 2016 CrossRef, Medline
35. Kaufman HL, Russell J, Hamid O, et al: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17:1374-1385, 2016 CrossRef, Medline
36. Antoniou AC, Pharoah PP, Smith P, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91:1580-1590, 2004 Medline
37. Song H, Dicks E, Ramus SJ, et al: Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J Clin Oncol 33:2901-2907, 2015 Link
38. Holter S, Borgida A, Dodd A, et al: Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol 33:3124-3129, 2015 Link
38a. Vasen H, Ibrahim I, Ponce CG, et al: Benefit of surveillance for pancreatic cancer in high-risk individuals: Outcome of long-term prospective follow-up studies from three European expert centers. J Clin Oncol 34:2010-2019, 2016
39. Yurgelun MB, Allen B, Kaldate RR, et al: Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149:604-613.e20, 2015
40. Zhang J, Walsh MF, Wu G, et al: Germline mutations in predisposition genes in pediatric cancer. N Engl J Med 373:2336-2346, 2015 CrossRef, Medline
41. Fransen M, Karahalios A, Sharma N, et al: Non-melanoma skin cancer in Australia. Med J Aust 197:565-568, 2012 CrossRef, Medline
42. Guy GP Jr, Machlin SR, Ekwueme DU, et al: Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011. Am J Prev Med 48:183-187, 2015 CrossRef, Medline
43. Chen AC, Martin AJ, Choy B, et al: A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 373:1618-1626, 2015 CrossRef, Medline
44. Zorogastua K, Erwin D, Thelemaque L, et al: Intrinsic factors of non-adherence to breast and cervical cancer screenings among Latinas. J Racial Ethn Health Disparities 3:658-666, 2016 CrossRef, Medline
45. National Cancer Institute: SEER stat fact sheets: Acute myeloid leukemia (AML). https://seer.cancer.gov/statfacts/html/amyl.html
46. Stone RM, Mandrekar S, Sanford BL, et al: The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY ). Blood 126:6, 2015
47. National Cancer Institute: SEER stat fact sheets: Acute lymphocytic leukemia (ALL). https://seer.cancer.gov/statfacts/html/alyl.html
48. Kantarjian HM, DeAngelo DJ, Stelljes M, et al: Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740-753, 2016 CrossRef, Medline
49. Shaw AT, Gandhi L, Gadgeel S, et al: Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: A single-group, multicentre, phase 2 trial. Lancet Oncol 17:234-242, 2016 CrossRef, Medline
50. US Food and Drug Administration: FDA approves new oral therapy to treat ALK-positive lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm476926.htm
51. Nokihara H, Kondo M, Kim YH, et al: Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. J Clin Oncol 34, 2016 (suppl; abstr 9008)
52. National Cancer Institute: SEER stat fact sheets: Myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html
53. Palumbo A, Chanan-Khan AAA, Weisel K, et al: Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. J Clin Oncol 34, 2016 (suppl; abstr LBA4) Medline
54. Cristofanilli M, Turner NC, Bondarenko I: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425-439, 2016 Medline
55. Finn RS, Martin M, Rugo HS, et al: PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J Clin Oncol 34, 2016 (suppl; abstr 507)
56. Hortobagyi GN, Stemmer SM, Burris HA, et al: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738-1748, 2016
57. US Food and Drug Administration: Palbociclib (IBRANCE capsules). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm487080.htm
58. National Cancer Institute: SEER stat fact sheets: Kidney and renal pelvis cancer. https://seer.cancer.gov/statfacts/html/kidrp.html
59. Choueiri TK, Escudier B, Powles T, et al: Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): Final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917-927, 2016 CrossRef, Medline
60. US Food and Drug Administration: Cabozantinib (CABOMETYX). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm
61. Janowitz T, Welsh SJ, Zaki K, et al: Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol 40:482-491, 2013 CrossRef, Medline
62. Ravaud A, Motzer RJ, Pandha HS, et al: Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med 375:2246-2254, 2016
63. Haas NB, Manola J, Uzzo RG, et al: Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-2016, 2016 CrossRef, Medline
64. Moore KN, Martin LP, Seward SM, et al: Preliminary single agent activity of IMGN853, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Phase I trial. J Clin Oncol 33, 2015 (suppl; abstr 5518)
65. Buckner JC, Shaw EG, Pugh SL, et al: Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344-1355, 2016 CrossRef, Medline
66. Park JR, Kreissman SG, London SG, et al: A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children’s Oncology Group (COG) study. J Clin Oncol 34, 2016 (suppl; abstr LBA3)
67. Venook AP, Niedzwiecki D, Innocenti F, et al: Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34, 2016 (suppl; abstr 3504)
68. Tejpar S, Stintzing S, Ciardiello F, et al: Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol [epub ahead of print on October 10, 2016]
69. Petrelli F, Tomasello G, Borgonovo K, et al: Prognostic survival associated with left-sided vs right-sided colon cancer. JAMA Oncol [epub ahead of print on October 27, 2016]
70. National Cancer Institute: SEER stat fact sheets: Pancreas cancer. https://seer.cancer.gov/statfacts/html/pancreas.html
71. Neoptolemos JP, Palmer D, Ghaneh P, et al: ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol 34, 2016 (suppl; abstr LBA4006)
72. Lancet JE, Uy GL, Cortes JE, et al: Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol 34, 2016 (suppl; abstr 7000)
73. Fleshman J, Branda M, Sargent DJ, et al: Effect of laparoscopic-assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes: The ACOSOG Z6051 randomized clinical trial. JAMA 314:1346-1355, 2015 CrossRef, Medline
74. Stevenson AR, Solomon MJ, Lumley JW, et al: Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: The ALaCaRT randomized clinical trial. JAMA 314:1356-1363, 2015 CrossRef, Medline
75. Goss PE, Ingle JN, Pritchard KI, et al: Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375:209-219, 2016 CrossRef, Medline
76. Pan H, Gray RG, Davies C, et al: Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). J Clin Oncol 34, 2016 (suppl; abstr 505)
77. Navari RM, Qin R, Ruddy KJ, et al: Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134-142, 2016 CrossRef, Medline
78. Basch E, Deal AM, Kris MG, et al: Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol 34:557-565, 2016 Link
79. Castaldi M, Safadjou S, Elrafei T, et al: A multidisciplinary patient navigation program improves compliance with adjuvant breast cancer therapy in a public hospital. Am J Med Qual [epub ahed of print on June 29, 2016]
80. Kaphingst KA, Blanchard M, Milam L, et al: Relationships between health literacy and genomics-related knowledge, self-efficacy, perceived importance, and communication in a medically underserved population. J Health Commun 21, 58-68, 2016 (suppl 1) CrossRef, Medline
81. National Cancer Institute: SEER stat fact sheets: Prostate cancer. https://seer.cancer.gov/statfacts/html/prost.html
82. Hamdy FC, Donovan JL, Lane JA, et al: 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415-1424, 2016 CrossRef, Medline
83. Shain AH, Yeh I, Kovalyshyn I, et al: The genetic evolution of melanoma from precursor lesions. N Engl J Med 373:1926-1936, 2015 CrossRef, Medline
84. Wheler JJ, Janku F, Naing A, et al: Cancer therapy directed by comprehensive genomic profiling: A single center study. Cancer Res 76:3690-3701, 2016 CrossRef, Medline
85. Hainsworth JD, Meric-Bernstam F, Swanton C, et al: Targeted therapy for advanced solid tumors based on molecular profiles: Early results from MyPathway, an open-label, phase IIa umbrella basket study. J Clin Oncol 34, 2016 (suppl; abstr LBA11511)
86. US Food and Drug Administration: FDA approves new pill to treat certain patients with non-small cell lung cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm
87. US Food and Drug Administration: Cobas EGFR mutation test v2. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm504540.htm
88. Jenkins S, Yang J, Ramalingam S, et al: 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC). J Thorac Oncol 11:S153-S154, 2016 (suppl) CrossRef, Medline
89. Oxnard GR, Thress KS, Alden RS, et al: Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer. J Clin Oncol 34:3375-3382, 2016 Link
90. Sacher AG, Paweletz C, Dahlberg SE, et al: Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol 2:1014-1022, 2016 CrossRef, Medline
91. Wakelee HA, Gadgeel SM, Goldman JW, et al: Epidermal growth factor receptor (EGFR) genotyping of matched urine, plasma and tumor tissue from non-small cell lung cancer (NSCLC) patients (pts) treated with rociletinib. J Clin Oncol 34, 2016 (suppl; abstr 9001)
92. Reckamp KL, Melnikova VO, Karlovich C, et al: A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma. J Thorac Oncol 11:1690-1700, 2016 CrossRef, Medline
93. Karlovich C, Goldman JW, Sun JM, et al: Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686). Clin Cancer Res 22:2386-2395, 2016 CrossRef, Medline
94. Zill OA, Mortimer S, Banks KC, et al: Somatic genomic landscape of over 15,000 patients with advanced-stage cancer from clinical next-generation sequencing analysis of circulating tumor DNA. J Clin Oncol 34, 2016 (suppl; abstr LBA11501) Medline
95. Tie J, Wang Y, Tomasetti C, et al: Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8:346ra92, 2016 CrossRef, Medline
96. Mirza MR, Monk BJ, Herrstedt J, et al: Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154-2164, 2016

ASCO, Immunotherapy 2.0, targeted therapy, complementair, niet-toxische middelen en behandelingen, immuuntherapie, personalised medicine, anti-PD medicijnen


Plaats een reactie ...

Reageer op "Immuuntherapie 2.0: ASCO komt met overzichtsrapport van de nieuwste ontwikkelingen bij kanker van afgelopen jaar en voorspellingen voor 2017"


Gerelateerde artikelen
 

Gerelateerde artikelen

Archief nieuwsberichten over >> Kankerpatiënten met een laag >> Nederlandse filmpremière >> Wim Hof die wereldberoemd >> Retour Hemel: documentaire >> Kankerpil - AOH1996, van professor >> Patienten met zeldzame vormen >> Sterkere MRI-scanner met nieuw >> Er dreigt een wereldwijde >> 34 procent van alle kankerpatienten >>